https://m2.mtmt.hu/ hun 2026-10-24 12:01 JournalArticle 36496755 APPROVED true 0 false 2026-09-23T19:03:24.414+0000 2026-09-23T19:01:58.900+0000 2025-12-16T10:20:26.185+0000 true 10062250 Molnár-Taga Márta /api/admin/10062250 Admin Molnár-Taga Márta (SE 4-es admin) true 10062250 2026-07-21T09:09:46.579+0000 2026-07-21T09:09:46.579+0000 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 1134514 Survey paper true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/1134514 Összefoglaló cikk SubType Összefoglaló cikk (Folyóiratcikk) 102 true 1134514 true 1 /api/category/1 Category Tudományos true 1 Országh, Erika true true /api/journal/10081425 REVIEWED NEURO-ONCOLOGY PRACTICE 2054-2577 2054-2585 true false 10081425 false 10081425 true 2054-2577 2054-2585 Journal FOREIGN 13 2 238 251 238 14 2025 Funding 2060976 /api/funding/2060976 (European Union’s HORIZON-MISS-2022-CANCER-01-03) false true Funding 2060977 /api/funding/2060977 (K135757) Támogató: NKFIH false true Funding 2060978 /api/funding/2060978 (TKP2021-EGA-24) false true true true 2025 true true true false true false NONE 2026-09-23 false 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 2 Q1 false false false false 2025-12-29T10:49:40.238+0000 Transzfúziológiai Tanszék (SE / AOK / K) 2 9 1 13 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 128933914 /api/authorship/128933914 Országh, Erika 1 0.07692308 true false false Országh Erika true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128933915 /api/authorship/128933915 Józwiak-Hagymásy, Judit 2 0.07692308 false false false Józwiak-Hagymásy Judit true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128933916 /api/authorship/128933916 Dóczi, Tamás 3 0.07692308 false false false Dóczi Tamás true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128933917 /api/authorship/128933917 Mezei, Dóra 4 0.07692308 false false false Mezei Dóra true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128933918 /api/authorship/128933918 Németh, Bertalan [Németh, Bertalan (Egészség-gazdaságtan), szerző] 5 0.07692308 false false false Author 10053881 /api/author/10053881 Németh Bertalan (Egészség-gazdaságtan) Németh Bertalan true 10053881 true Németh Bertalan true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128933919 /api/authorship/128933919 Varga, Hédi 6 0.07692308 false false false Varga Hédi true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128933920 /api/authorship/128933920 Tordai, Attila ✉ [Tordai, Attila (Orvostudomány), szerző] Transzfúziológiai Tanszék (SE / AOK / K) 7 0.077 false false true Author 10002439 /api/author/10002439 Tordai Attila (Orvostudomány) Tordai Attila true 10002439 true Tordai Attila true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128933921 /api/authorship/128933921 Kazda, Tomas 8 0.07692308 false false false Kazda Tomas true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128933922 /api/authorship/128933922 Gorlia, Thierry 9 0.07692308 false false false Gorlia Thierry true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128933923 /api/authorship/128933923 Quoilin, Caroline 10 0.07692308 false false false Quoilin Caroline true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128933924 /api/authorship/128933924 Preusser, Matthias 11 0.07692308 false false false Preusser Matthias true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128933925 /api/authorship/128933925 Minniti, Giuseppe 12 0.07692308 false false false Minniti Giuseppe true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128933926 /api/authorship/128933926 Csanádi, Marcell 13 0.07692308 false true false Csanádi Marcell true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 30334759 /api/publicationidentifier/30334759 DOI: 10.1093/nop/npaf113 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.1093/nop/npaf113 https://doi.org/10.1093/nop/npaf113 false true PublicationIdentifier 30334760 /api/publicationidentifier/30334760 WoS: 001632126500001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001632126500001 https://www.webofscience.com/wos/woscc/full-record/001632126500001 false true PublicationIdentifier 32444489 /api/publicationidentifier/32444489 Scopus: 105038402677 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 105038402677 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105038402677 true true PublicationIdentifier 32444491 /api/publicationidentifier/32444491 PubMed: 42111041 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 42111041 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=42111041&dopt=Abstract true true SjrRating 11602980 /api/sjrrating/11602980 sjr:Q1 (2025) Scopus - Medicine (miscellaneous) NEURO-ONCOLOGY PRACTICE 2054-2577 2054-2585 568 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2701 /api/classificationexternal/2701 Scopus - Medicine (miscellaneous) true 2701 true Q1 DIRECT true true Reference 70838066 /api/reference/70838066 1. Alexander 2017: Adult glioblastoma., J Clin Oncol., 35, p. 2402, DOI: 10.1200/JCO.2017.73.0119 1 10.1200/JCO.2017.73.0119 false true Reference 70838067 /api/reference/70838067 2. Dietrich 2 false true Reference 70838068 /api/reference/70838068 3. Berger 2022: World Health Organization 2021 classification of central nervous system tumors and implications for therapy for adult-type gliomas: a review., JAMA Oncol., 8, p. 1493, DOI: 10.1001/jamaoncol.2022.2844 3 10.1001/jamaoncol.2022.2844 false true Reference 70838069 /api/reference/70838069 4. Gittleman 2017: An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825., Neuro Oncol, 19, p. 669 4 false true Reference 70838070 /api/reference/70838070 5. Batchelor 5 false true Reference 70838071 /api/reference/70838071 6. Batchelor 6 false true Reference 70838072 /api/reference/70838072 7. Shih 7 false true Reference 70838073 /api/reference/70838073 8. Stupp 2005: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma., N Engl J Med., 352, p. 987, DOI: 10.1056/NEJMoa043330 8 10.1056/NEJMoa043330 false true Reference 70838074 /api/reference/70838074 9. Minniti 2021: Current status and recent advances in reirradiation of glioblastoma., Radiat Oncol., 16, p. 36, DOI: 10.1186/s13014-021-01767-9 9 10.1186/s13014-021-01767-9 false true Reference 70838075 /api/reference/70838075 10. Herrlinger 2019: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial., Lancet, 393, p. 678, DOI: 10.1016/S0140-6736(18)31791-4 10 10.1016/S0140-6736(18)31791-4 false true Reference 70838076 /api/reference/70838076 11. Guo 2022: Tumor-treating fields in glioblastomas: past, present, and future., Cancers (Basel, 14, p. 3669, DOI: 10.3390/cancers14153669 11 10.3390/cancers14153669 false true Reference 70838077 /api/reference/70838077 12. Goel 2021: Economic implications of the modern treatment paradigm of glioblastoma: an analysis of global cost estimates and their utility for cost assessment., J Med Econ, 24, p. 1018, DOI: 10.1080/13696998.2021.1964775 12 10.1080/13696998.2021.1964775 false true Reference 70838078 /api/reference/70838078 13. Miller 2014: Current challenges in health economic modeling of cancer therapies: a research inquiry., Am Health Drug Benefits., 7, p. 153 13 false true Reference 70838079 /api/reference/70838079 14. Bullement 2019: A review of recent decision-analytic models used to evaluate the economic value of cancer treatments., Appl Health Econ Health Policy., 17, p. 771, DOI: 10.1007/s40258-019-00513-3 14 10.1007/s40258-019-00513-3 false true Reference 70838080 /api/reference/70838080 15. Roets 2024: Patient-reported outcomes in randomized clinical trials of systemic therapy for advanced soft tissue sarcomas in adults: a systematic review., Crit Rev Oncol Hematol., 197, p. 104345, DOI: 10.1016/j.critrevonc.2024.104345 15 10.1016/j.critrevonc.2024.104345 false true Reference 70838081 /api/reference/70838081 16. Lorenzovici 2023: Systematic literature review of economic evaluations of treatment alternatives in chronic lymphocytic leukemia., BioDrugs., 37, p. 219, DOI: 10.1007/s40259-023-00583-9 16 10.1007/s40259-023-00583-9 false true Reference 70838082 /api/reference/70838082 17. Messali 2014: A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments., Pharmacoeconomics., 32, p. 1201, DOI: 10.1007/s40273-014-0198-y 17 10.1007/s40273-014-0198-y false true Reference 70838083 /api/reference/70838083 18. Page 2021: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews., BMJ, 372, p. n71, DOI: 10.1136/bmj.n71 18 10.1136/bmj.n71 false true Reference 70838084 /api/reference/70838084 19. Országh 19 false true Reference 70838085 /api/reference/70838085 20. Haddaway 20 false true Reference 70838086 /api/reference/70838086 21. Adarkwah 2016: Risk of bias in model-based economic evaluations: the ECOBIAS checklist., Expert Rev Pharmacoecon Outcomes Res., 16, p. 513, DOI: 10.1586/14737167.2015.1103185 21 10.1586/14737167.2015.1103185 false true Reference 70838087 /api/reference/70838087 22. Chen 2021: Cost-effectiveness of short-course radiation plus temozolomide for the treatment of newly diagnosed glioblastoma among elderly patients in China and the United States., Front Pharmacol, 12, p. 743979, DOI: 10.3389/fphar.2021.743979 22 10.3389/fphar.2021.743979 false true Reference 70838088 /api/reference/70838088 23. Connock 2021: A comparison of published time invariant Markov models with Partitioned Survival models for cost effectiveness estimation; three case studies of treatments for glioblastoma multiforme., European J Health Econ., 22, p. 89, DOI: 10.1007/s10198-020-01239-z 23 10.1007/s10198-020-01239-z false true Reference 70838089 /api/reference/70838089 24. Fischer 2016 24 false true Reference 70838090 /api/reference/70838090 25. Kovic 2015: Economic evaluation of bevacizumab for the first-line treatment of newly diagnosed glioblastoma multiforme., J Clin Oncol, 33, p. 2296, DOI: 10.1200/JCO.2014.59.7245 25 10.1200/JCO.2014.59.7245 false true Reference 70838091 /api/reference/70838091 26. Messali 2013: The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States., Neuro-Oncology., 15, p. 1532, DOI: 10.1093/neuonc/not096 26 10.1093/neuonc/not096 false true Reference 70838092 /api/reference/70838092 27. NICE 2007 27 false true Reference 70838093 /api/reference/70838093 28. Waschke 2018: Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany., J Neurooncol, 138, p. 359, DOI: 10.1007/s11060-018-2804-x 28 10.1007/s11060-018-2804-x false true Reference 70838094 /api/reference/70838094 29. Chinot 2014: Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma., N Engl J Med., 370, p. 709, DOI: 10.1056/NEJMoa1308345 29 10.1056/NEJMoa1308345 false true Reference 70838095 /api/reference/70838095 30. Gilbert 2014: A randomized trial of bevacizumab for newly diagnosed glioblastoma., N Engl J Med., 370, p. 699, DOI: 10.1056/NEJMoa1308573 30 10.1056/NEJMoa1308573 false true Reference 70838096 /api/reference/70838096 31. Bernard-Arnoux 2016: The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma., Neuro Oncol., 18, p. 1129, DOI: 10.1093/neuonc/now102 31 10.1093/neuonc/now102 false true Reference 70838097 /api/reference/70838097 32. Connock 2019: Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model., J Neuro-Oncol., 143, p. 605, DOI: 10.1007/s11060-019-03197-w 32 10.1007/s11060-019-03197-w false true Reference 70838098 /api/reference/70838098 33. Nino de Rivera Guzman 2023: EE363 cost-effectiveness analysis of adding tumor treating fields therapy to temozolomide versus temozolomide only in patients with glioblastoma in France., Value Health, 26, p. S121, DOI: 10.1016/j.jval.2023.09.629 33 10.1016/j.jval.2023.09.629 false true Reference 70838099 /api/reference/70838099 34. Guzauskas 2019: Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study., J Med Econ., 22, p. 1006, DOI: 10.1080/13696998.2019.1614933 34 10.1080/13696998.2019.1614933 false true Reference 70838100 /api/reference/70838100 35. Stupp 2015: Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial., JAMA., 314, p. 2535, DOI: 10.1001/jama.2015.16669 35 10.1001/jama.2015.16669 false true Reference 70838101 /api/reference/70838101 36. Stupp 2017: Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial., JAMA, 318, p. 2306, DOI: 10.1001/jama.2017.18718 36 10.1001/jama.2017.18718 false true Reference 70838102 /api/reference/70838102 37. Garcia Lopez 2014: Cost-effectiveness analysis of bevacizumab, fotemustine and extended-dose temozolomide in patients with recurrent glioblastoma in Spain., Value Health., 17, p. A638, DOI: 10.1016/j.jval.2014.08.2298 37 10.1016/j.jval.2014.08.2298 false true Reference 70838103 /api/reference/70838103 38. Martikainen 2005: Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme., Pharmacoeconomics, 23, p. 803, DOI: 10.2165/00019053-200523080-00006 38 10.2165/00019053-200523080-00006 false true Reference 70838104 /api/reference/70838104 39. Baguet 2019: Cost-effectiveness of [18F] fluoroethyl-L-tyrosine for temozolomide therapy assessment in patients with glioblastoma., Front Oncol, 9, p. 814, DOI: 10.3389/fonc.2019.00814 39 10.3389/fonc.2019.00814 false true Reference 70838105 /api/reference/70838105 40. Chandra 2020: Insurance type impacts the economic burden and survival of patients with newly diagnosed glioblastoma., J Neurosurg., 133, p. 89, DOI: 10.3171/2019.3.JNS182629 40 10.3171/2019.3.JNS182629 false true Reference 70838106 /api/reference/70838106 41. Garside 2007: The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation., Health Technol Assess., 11, p. iii, DOI: 10.3310/hta11450 41 10.3310/hta11450 false true Reference 70838107 /api/reference/70838107 42. Vrdoljak 2019: Expenditures on oncology drugs and cancer mortality-to-incidence ratio in Central and Eastern Europe., Oncologist, 24, p. e30, DOI: 10.1634/theoncologist.2018-0093 42 10.1634/theoncologist.2018-0093 false true Reference 70838108 /api/reference/70838108 43. Xu 2024: Cost-effectiveness analysis of 11 pharmacotherapies for recurrent glioblastoma in the USA and China., Ther Adv Med Oncol, 16, p. 17588359241264727, DOI: 10.1177/17588359241264727 43 10.1177/17588359241264727 false true Reference 70838109 /api/reference/70838109 44. Preusser 2024: Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study., Trials., 25, p. 366, DOI: 10.1186/s13063-024-08213-7 44 10.1186/s13063-024-08213-7 false true Reference 70838110 /api/reference/70838110 45. Xu 2023: Efficacy and safety of pharmacotherapy for recurrent high-grade glioma: a systematic review and network meta-analysis., Front Pharmacol, 14, p. 1191480, DOI: 10.3389/fphar.2023.1191480 45 10.3389/fphar.2023.1191480 false true /api/publication/36496755 Országh Erika et al. Methodological aspects of economic evaluations and health economic models in glioblastoma: A systematic literature review. (2025) NEURO-ONCOLOGY PRACTICE 2054-2577 2054-2585 13 2 238-251<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" >Országh Erika </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Józwiak-Hagymásy Judit </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Dóczi Tamás </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Mezei Dóra </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10053881"><a href="/gui2/?type=authors&mode=browse&sel=10053881" target="_blank">Németh Bertalan (<span class="authorship-author-name">Németh Bertalan</span> <span class="authorAux-mtmt"> Egészség-gazdaságtan</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Varga Hédi </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10002439"><a href="/gui2/?type=authors&mode=browse&sel=10002439" target="_blank">Tordai Attila ✉ (<span class="authorship-author-name">Tordai Attila</span> <span class="authorAux-mtmt"> Orvostudomány</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Transzfúziológiai Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Kazda Tomas </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Gorlia Thierry </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Quoilin Caroline </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Preusser Matthias </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Minniti Giuseppe </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Csanádi Marcell </span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;36496755" target="_blank">Methodological aspects of economic evaluations and health economic models in glioblastoma: A systematic literature review</a></div> <div> <span class="journal-title">NEURO-ONCOLOGY PRACTICE</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/2054-2577">2054-2577</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/2054-2585">2054-2585</a>)</span>: <span class="journal-volume">13</span> <span class="journal-issue">2</span> <span class="page"> pp 238-251 </span> <span class="year">(2025)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.1093/nop/npaf113" target="_blank" href="https://doi.org/10.1093/nop/npaf113"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001632126500001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001632126500001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="105038402677" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105038402677"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="42111041" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=42111041&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Medicine (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Neurology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Oncology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> </div></OnlyViewableByAuthor> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;36496755&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 2 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 36496755</span> | <span class="status-data status-APPROVED"> Nyilvános </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Összefoglaló cikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">WoS-XML</span> </div> <div class="funder"> (European Union’s HORIZON-MISS-2022-CANCER-01-03), (K135757) Támogató: NKFIH, (TKP2021-EGA-24) </div> <div class="lastModified">Utolsó módosítás: 2026.09.23. 21:01 Németh Bertalan (Egészség-gazdaságtan) </div> </div></div>